Bristol-Myers Squibb Co (NYSE:BMY)
| 63.82 Delayed Data As of Dec 13 |  -0.12 / -0.19%Today’s Change | 42.48 Today|||52-Week Range 64.75 | +22.78% Year-to-Date |
Latest BMY News | Press Releases
| After Its Celgene Acquisition, Bristol-Myers Squibb's Future Looks Bright Dec 12 / MotleyFool.com - Paid Partner Content | Better Buy: Pfizer vs. Bristol-Myers Squibb Dec 08 / MotleyFool.com - Paid Partner Content |
| Here's Why You Should Own Amgen Stock in 2020 Dec 12 / MotleyFool.com - Paid Partner Content | Bristol Myers Squibb: A Cash-Generating Machine at a Cheap Price Dec 07 / MotleyFool.com - Paid Partner Content |
| Here’s Why bluebird bio Shares Jumped Almost 12% Today Dec 10 / MotleyFool.com - Paid Partner Content | 2 Breast Cancer Fighting Stocks to Invest In Dec 06 / MotleyFool.com - Paid Partner Content |
| Sanofi Is Paying a 172% Premium to Buy Synthorx -- and It Sounds Like a Good Deal for Both Dec 10 / MotleyFool.com - Paid Partner Content | 3 Biotech Stocks With a Lot to Prove at ASH 2019 Dec 02 / MotleyFool.com - Paid Partner Content |
| Better Buy: Biogen vs. Amgen Dec 08 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 63.94 |
| Today’s open | 64.04 |
| Day’s range | 63.79 - 64.75 |
| Volume | 14,569,249 |
| Average volume (3 months) | 15,011,047 |
| Market cap | $149.6B |
Data as of 6:30pm ET, 12/13/2019
Growth & Valuation
| Earnings growth (last year) | +392.14% |
| Earnings growth (this year) | +8.95% |
| Earnings growth (next 5 years) | +14.00% |
| Revenue growth (last year) | +8.59% |
| P/E ratio | 18.4 |
| Price/Sales | 3.77 |
| Price/Book | 7.38 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ABBVAbbVie | -0.89 | -1.00% |
| AZNAstraZeneca | +0.44 | +0.92% |
| SNYSanofi | +0.28 | +0.57% |
| LLYEli Lilly and Co | -0.17 | -0.14% |
Data as of 6:30pm ET, 12/13/2019
Financials
| Next reporting date | January 27, 2020 |
| EPS forecast (this quarter) | $0.91 |
| Annual revenue (last year) | $22.6B |
| Annual profit (last year) | $4.9B |
| Net profit margin | 21.81% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters New York, New York |
Forecasts
